Objective: Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor prognosis. Circulating tumor cells (CTCs) are a promising predictor for breast cancer prognoses but their reliability regarding progression-free survival (PFS) is controversial. We aim to verify their predictive value in TNBC.
Introduction
Triple negative breast cancer (TNBC) accounts for nearly 15% of all breast cancers and is defined by the absence of estrogen receptors (ER), progesterone receptors (PgR) and human epidermal growth factor receptor 2 (HER2) breast cancer cell growth and also served as targets of specific therapeutic drugs. Until now, only a few moleculedirected therapies, including poly(ADP-ribose) polymerase (PARP) inhibitors, were available for TNBC patients (2, 3) . Chemotherapy and radiotherapy are still standard treatments for patients with early-stage or advanced-stage TNBC, but their long-term results are not optimistic (4) .
As currently-used cancer-related biomarkers do not precisely reflect tumor response in advanced-stage TNBC (5) , clinical decisions mainly rely on radiological evaluation of tumor burden at regular intervals, which cannot be intensively used during a therapeutic course (4) . A better real-time evaluating system for TNBC is urgently required.
In this setting, circulating tumor cells (CTCs) are considered to be potential real-time, minimally invasive "liquid biopsies". CTCs have been shown capable of providing information on dynamic changes in tumor burden and even vital genetic information about the targeted tumor from a blood draw (6) . Although numerous studies have proven CTCs to be an independent prognostic factor in all stages of breast cancer, until now, the only U.S. Food & Drug Administration-approved method of detecting CTC is the CellSearch assay (7) . However, many epithelial cell adhesion molecule (EpCAM)-based CTCisolation technologies, including CellSearch, have prognostic limitations for certain breast cancer subtypes, especially TNBC (8,9). Previous reports showed that baseline CTC enumeration can successfully predict overall survival (OS) of TNBC patients, but its predictive value for progression-free survival (PFS) is still controversial. In 2012, Munzone E et al. first evaluated the prognostic value of CTCs in different immunohistochemically (IHC)-defined breast cancer subtypes. They found that baseline CTC counts detected by CellSearch were borderlinesignificantly associated with OS but not with PFS, in TNBC patients who were receiving new courses of systemic therapy (8). Thereafter, three other studies also confirmed that baseline CTC counts were not predictive for both PFS and OS in TNBC patients (10) (11) (12) . Particularly in 2015, a phase II clinical trial (TBCRC001) that used two parallel CTC-detecting technologies [CellSearch and immunomagnetic enrichment and flow cytometry (IE/FC)] again showed that the CTC status (as detected by both methods at baseline) was not predictive for time-to-progression in 102 women with TNBC (13) . In contrast, results from another phase II trial (TBCRC019) showed that baseline CTC count higher than 5 CTCs per 7.5 mL whole blood is a negative prognostic factor for PFS in TNBC patients (14) . Similar results were also reported by another study (15) . However, these two studies drew their conclusions based on rather small patient cohorts (n=52 and n=16, respectively). We therefore conducted a prospective investigation using our previously reported nanotechnology-based CTC isolation system (Pep@MNPs) (16) , to verify the prognostic efficacy of EpCAM-based CTC enumeration in TNBC patients.
For the first time, we also took peripheral lymphocyte enumeration into consideration to optimize the prognostic power of EpCAM-based CTCs enumeration in TNBC patients.
Materials and methods

Patients and samples
For this study, we enrolled 75 consecutive TNBC patients who received treatment at the Peking University Cancer Hospital & Institute from March 2014 to December 2016. The study was approved by the Medical Ethical Committee of Peking University Cancer Hospital & Institute (Approval No. 2013KT29). Our eligibility criteria were: 1) recurrent and metastatic breast cancer; 2) absence of ER, PgR or HER2 expression; 3) about to begin a new line of therapy; 4) expected survival time of at least 3 months; 5) measurable lesions; and 6) patient's written informed consent.
We defined ER and PgR positivity by IHC-tested Allred scores ranging from 3 to 8, using antibodies against ER (Immunotech, Marseilles, France) and PgR (Novocastra Laboratories, Newcastle, UK). IHC staining against HER2 (Abcam PLC, Cambridge, UK) was categorized in intensity as 0, 1+, 2+ or 3+; 0-1+ was considered as HER2 -, 3+ as HER2 + , and HER2 amplification of 2+ samples was confirmed by fluorescence in situ hybridization (FISH).
We collected peripheral blood samples from the 75 patients, using their blood draws at baseline (time of inclusion) for CTC and lymphocyte enumeration. Of the 75 patients, 10 had subsequent blood draws at regular tumor evaluation intervals. Clinicopathological and complete ongoing follow-up information was recorded for all the patients at the time of blood collection. For each patient, one tube containing 8.0 mL peripheral blood was collected in CellSave® (Immunivest Corporation, Wilmington DE, USA) collection tubes for the Pep@MNPs assays. Samples were maintained at room temperature and processed within 96 h; only 2.0 mL blood was used for Pep@MNPs enumeration. Details of the Pep@MNPs technique have been described previously (16) .
Lymphocytes phenotype by flow cytometry
Phenotypes were ascertained using whole blood. Peripheral lymphocytes were stained using the appropriate antibodies: CD3-PC5/CD4-FITC/CD8-PE (IM1650, Beckman Coulter, California, USA), CD3-FITC/(CD16 + /CD56 + )-PE (A07735, Beckman Coulter), CD (14+16)-FITC/CD85k (ILT3)-PE/CD33-PC5 (A23413, Beckman Coulter), CD4-FITC (A007750, Beckman Coulter, CD8-FITC (A07756, Beckman Coulter), CD19-PC5 (A07771; Beckman Coulter), CD25-PE (A07774, Beckman Coulter), CD314/NKG2D PE-Cyanine7 (25-5878-41, eBioscience, San Diego, CA, US), and CD159a-PC7 (B10246, Beckman Coulter). Tests were performed on FC500 flow cytometer (Beckman Coulter).
In short, 100 μL of fresh whole blood from TNBC patients were incubated with the appropriate antibodies on a rocking platform for 30 min. Erythrocytes were lysed with OptiLyse® C (A11895, Beckman Coulter) as directed by the manufacture's protocol. Before and after reading patient samples, fluorescence intensities of the FACS Canto were standardized over time with PMT 7-Color Setup Beads (335775, BD Biosciences) to compensate for fluorescence intensity variability. The gating strategy consisted of eliminating doublets based on FCS-A and FCS-H parameters, followed by removal of dead cells. Levels of different peripheral lymphocyte subtypes were expressed as percentages of total lymphocytes (%). Phenotyping and grading of each lymphocyte subtype were set up according to previously reported standards (17) (18) (19) (20) . Detailed information is shown in Supplementary Table S1 and Supplementary Figure S1 .
CTC isolation and enumeration by Pep@MNPs
We counted CTCs using the Pep@MNPs method as previously described (16) . In brief, an EpCAM recognition peptide is attached with iron oxide magnetic nanoparticles (MNPs) via biotin-avidin interaction. For ease of detection, 5.0 μL pre-vortexed Pep@MNPs (10 mg Fe/mL) was added to 2.0 mL peripheral blood samples, and incubated with gentle shaking at 37 °C for 30 min. The Pep@MNPs-CTC complexes were subsequently isolated and washed with PBS at least 3 times under a magnetic field; the captured CTCs were then stained by multiple color immunocytochemistry: 4',6-diamidino-2-phenylindole (DAPI) for cell nuclei, CD45-phycoerythrin for leukocytes (negative selection) and CK19-fluorescein isothiocyanate for cytokeratin (CK; positive selection, which was used to distinguish epithelial cells from leukocytes). Further identification and counting of CTCs were performed using ZeissVert A1 fluorescent microscope (Carl Zeiss Microscopy GmbH, München, Germany).
Definition of CTC-natural killer cell (CTC-NK) threshold
To generate the combined CTC and peripheral NK cell enumeration (CTC-NK), we used a binary logistic regression analysis which includes CTC and NK. In the CTC-NK regression equation, the response variable was whether patients with PFS≤6.0 months (poor prognosis), or with PFS>6 months (favorable prognosis). The predictive probabilities of each CTC-NK combinations were calculated and subsequently subjected to receiver operating characteristic curve (ROC) analysis for area under the curve (AUC). The true class for ROC analysis was patient with poor prognosis or with favorable prognosis. Thereafter, the AUCs for CTC, NK and CTC-NK were compared. Finally, the CTC-NK combination with maximum Youden-index was set as the threshold of CTC-NK. Youden-index was calculated by the following formula: sensitivity + specificity -1.
Statistical analysis
The main objective was to test whether PFS was associated with CTC status at baseline in TNBC patients; and secondarily to find any correlations between CTC count, metastatic status, or peripheral lymphocyte ratios. PFS was calculated from the date of inclusion until the date of tumor progression (per clinical or imaging diagnosis) or cancer related death.
The positive rates of NK-associated activating receptor between health control and TNBC were compared by independent t-test (two-tailed). Data were expressed as . Categorical variables (such as histological type, metastatic status and family history) were compared by Chi-square or Fisher's exact test. Hierarchical variables (such as tumor grade or tumor stage) were compared by the CochranArmitage trend test. Correlations between CTC status and different peripheral lymphocyte subtypes were evaluated with Spearman rank correlation test, with CTC detection as the outcome variable of interest. The predictive probabilities of CTC-NK combination were calculated by logistic regression. The AUC of CTC, NK and CTC-NK was calculated by ROC analysis. Kaplan-Meier survival curves were computed according to CTC status alone or combined CTC and NK cell status. The PFS of each group was compared using log-rank tests. For all analyses, P<0.05 indicates statistically significant. All analyses were performed using IBM SPSS Statistics (Version 19.0; IBM Corp., New York, USA).
Results
Patient characteristics
The median age at diagnosis of the 75 patients in this cohort was 49 (range: 30- 
Clinical relevance of baseline CTC count in TNBC
At baseline, the median CTC count of this cohort was 2.0 CTC/2 (range: 0.0-126.0 CTC/2) mL. The cut-off for CTC status used in the present study was defined by our previous study (CTC>2.0:>2.0 CTC/2 mL; CTC≤2.0: ≤2.0 CTC/2 mL). The CTC detection rate was 73.3% for the cohort as a whole. No significant correlation was found between baseline CTC status and initial tumor stage (P=0.164), tumor grade (P=0.781), histological type (P=0.084) or number of visceral metastatic sites (P=0.575) ( Table 1) . However, in the first-line therapy subgroup, 76.0% of the patients were CTC>2.0. Baseline CTC status was found to positively correlate with lung metastases (P=0.034) and number of visceral metastatic sites (P=0.037) ( Table 2) .
Positive correlation between baseline CTCs and functional peripheral NK cells
As chemotherapy can cause hematological toxicity (such as lymphocytopenia), we explored associations between CTC status and peripheral lymphocyte ratios only among patients who had not yet undergone any treatment. As the data show, baseline CTC status was not significantly associated with most lymphocyte subtypes. However, CTC status and peripheral NK ratios were positively correlated (P=0.032; Table 3 ). We also longitudinally monitored both CTC counts and peripheral NK cell ratios at regular intervals after chemotherapy in some patients, and found similar tendencies in variations of CTC counts and peripheral NK cell ratios in six patients. Although peripheral NK cell ratios and CTC status were positive correlated, the functional integrity of NK cells in TNBC patients still needed to be evaluated. In doing so, we compared positive rates of NK-associated activating receptor (NKG2D, also known as CD314) and inhibitory receptor (NKG2A, also known as CD159a) between healthy controls and the TNBC patients. The positive rate was defined as the percentage of NKG2A + or NKG2D + peripheral NK cells to active peripheral NK cells (CD3 -/CD56 + /CD16 + ), based on the gating strategies shown in Figure 1A , B. As the data indicate ( Figure 1C) 
Prognostic value of baseline CTC for PFS
In consideration of the conflicting reports on the prognostic value of EpCAM + CTC in TNBC with respect to PFS, we carried out a revalidation experiment using our self-developed CTC isolation system (Pep@MNPs). We divided the cohort into CTC>2.0 and CTC≤2.0 subgroups and compared their PFS. Regardless of lines of therapy, median PFS did not significantly differ between the CTC>2.0 group (5.0 months) and the CTC≤2.0 group (6.0 months; P=0.118; Figure 2A) . However, among patients who were undergoing first-line therapy, significantly shorter median PFS was observed for the CTC>2.0 group (6.0 months) than the CTC≤2.0 group (15.0 months; P=0.033; Figure 2B ).
Enhanced prognostic power of CTC by adding NK cell enumeration
As baseline CTC status and peripheral NK cell ratios were positively correlated, and immune factors reportedly have prognostic value for breast cancer, we sought better predictions for PFS of TNBC by considering CTC and Figure 3B ).
Discussion
The prognostic value of EpCAM-dependent CTCs in metastatic breast cancer has been clearly demonstrated. However, breast cancer is a heterogeneous disease. According to previous reports, 3%-10% of breast cancers do not express EpCAM (21) (22) (23) . Several clinical features, including molecular subtype, reportedly affect CTC detection rate. For instance, CTC were found more in luminal HER2 -patients than in those with HER2 + cancer or TNBC (24) . At least one explanation for this phenomenon is low EpCAM expression and more CTC, circulating tumor cell; TNBC, triple-negative breast cancer. Baseline CTC status consists of CTC positivity (>2 CTC/2 mL) and CTC negativity (≤2 CTC/2 mL). mesenchymal phenotypes of HER2 + and TNBC tumors. The CellSearch platform indicates that CTC detection rates in TNBC patients range from 33.3% to 81.0% (8, 10, 11, 13, 15, 25, 26) ; as CTCs in the present study were detected in 55 out of our 75 patients (73.3%), the efficacy of our CTC isolation system (Pep@MNPs) for TNBC seems to be satisfactory. We therefore sought to determine the association between baseline CTC status and other clinical parameters of TNBC, especially PFS. Using the threshold defined in our previous study (2.0 CTC/2 mL whole blood) (16), we found baseline CTC status was positively correlated with lung metastasis in first-line patients (P=0.034) and number of metastatic sites (P=0.037). However, this correlation became insignificant in the cohort as a whole, regardless of lines of therapy (P=0.131). We believe it partly due to the loss of epithelial markers, including EpCAM, as tumors progressed through multiple lines of therapy (27) . Notably, we also found a positive correlation between baseline CTC status and peripheral NK cells ratio in firstline TNBC patients. We also longitudinally monitored variations of both NK cell ratios and CTC numbers over times in several patients. Despite the effect of antitumor therapy on peripheral lymphocyte numbers (17, 20) , we observed synchronized variation curves for CTC numbers and peripheral NK cell ratios in most patients.
The bloodstream is a harsh environment for tumor cells, in which CTCs might face many fierce attacks, including elimination by immune cells (28) . After CTCs are shed into circulation, they can be recognized and eliminated by NK cells, neutrophils, macrophages or cytotoxic T-cells (29) (30) (31) (32) , which supports the positive correlation between CTC status and peripheral NK cells ratio found in our study. However, in breast cancer patients, some peripheral lymphocytes, such as T helper cells and monocytic dendritic cells, are reportedly more vulnerable and likely to undergo apoptosis, especially in CTC positive patients (as defined by CellSearch) (33, 34) . To assure functional integrity of peripheral NK cells in TNBC patients, we evaluated the classic NK-associated inhibitory receptor, NKG2A, and activating receptor, NKG2D, and found that neither NKG2A (P=0.422) nor NKG2D (P=0.125) was abnormally expressed in TNBC patients compared with healthy controls; this indicates that peripheral NK cells normally responded to EpCAM + CTCs in TNBC.
The main purpose of present study was to determine whether baseline CTC counts were related to PFS in TNBC patients, regardless of lines of therapy. In this study cohort as a whole, the CTC≤2.0 and CTC>2.0 groups did not significantly differ in PFS (using 2.0 CTC/2 mL as the cutoff; P=0.118). However, as discussed above, the total TNBC cohort contained multiline-therapy patients whose cancers might lose EpCAM expression during the course of tumor progression. This might explain the impaired prognostic power of EpCAM-dependent CTC enumeration in TNBC patients, regardless of lines of therapy. This speculation is supported by our data showing that baseline CTC status has predictive values regarding PFS (P=0.033) in TNBC patients undergoing first-line treatment. Some recent pilot studies that combined CTC enumeration with other clinical parameters, including tumor stage, presence of visceral metastasis, performance status and gene expression, were capable to estimate survival or tumor response (35, 36) . The presence of certain lymphocytes (such as tumor-infiltrating lymphocytes) has been reported as independent prognostic factors for OS and PFS (8, 20, (37) (38) (39) in breast cancer. In view of these findings, we wondered if we could optimize the prognostic performance of baseline CTC in TNBC by adding peripheral lymphocyte enumeration. The presence of active peripheral NK cells (CD3 -/CD56 + /CD16 + ) can clear CTCs or maintain them at certain levels (37, 40) . However, some CTCs could also develop escape or resistance mechanisms against NK cell-mediated elimination (41) (42) (43) . These better evolved CTCs are the so-called "NK-resistant CTCs". This terminology was first used in prostate cancer (44) . The check-and-balance relationship between CTCs and NK cells may have an important implication for the prognosis of TNBC patients, and the presence of NKresistant CTCs may portend a worse outcome in TNBC patients. According to this speculation, the CTC>2.0 TNBC patients with a certain level of peripheral NK cells should have shorter PFS than other patients. As expected, when we used the CTC-NK combined enumeration thresholds of >2.0 CTC/2 mL and NK>8.0%, we could stratify TNBC patients in terms of PFS, regardless of their lines of therapy (P=0.049). The ROC curve analysis also showed that CTC-NK had better AUC as compared to CTC or NK proportion alone (0.659 vs. 0.402 and 0.659 vs. 0.410). These findings confirm the advantage of CTC-NK enumeration in predicting FPS of TNBC patients.
Conclusions
In this study, we reported that: 1) the EpCAM-based CTC assay is more sensitive to lung metastasis in TNBC patients; 2) baseline CTC status is positively correlated with functional peripheral NK cell ratio in TNBC; 3) baseline CTC counts can predict PFS only in first-line TNBC patients but not TNBC patients as a whole, without respect to lines of therapy; 4) but baseline CTC combined with NK enumeration (CTC-NK) can predict PFS of TNBC patients regardless of their lines of therapy. Thus CTC-NK combined enumeration could be a useful prognostic tool for patients with TNBC. Future studies are needed to explore the biological nature and clinical significance of NK-resistant CTCs in breast cancer. Stage IV at initial diagnosis 6 (8.0) TNBC, triple-negative breast cancer.
